TABLE 2.
Summary of delafloxacin activity by MIC against baseline S. aureus from an ABSSSI site or blood by levofloxacin susceptibilitya
| Organism | Levofloxacin-susceptible isolates |
Levofloxacin-nonsusceptible isolates |
||||||
|---|---|---|---|---|---|---|---|---|
| No. | Delafloxacin MIC (μg/ml) |
No. | Delafloxacin MIC (μg/ml) |
|||||
| 50% | 90% | Range | 50% | 90% | Range | |||
| S. aureus | 455 | 0.008 | 0.008 | 0.002–0.12 | 232 | 0.25 | 0.25 | 0.004–4 |
| MRSA | 101 | 0.008 | 0.008 | 0.002–0.12 | 195 | 0.25 | 0.25 | 0.004–4 |
| MSSA | 358 | 0.008 | 0.008 | 0.002–0.12 | 39 | 0.12 | 0.25 | 0.004–0.5 |
a
Results are from pooled data for the delafloxacin and comparator treatment arms for the MITT population. MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus; No., number of available MIC values from isolates cultured at the baseline from the primary infection site or blood.